Key result
Genous bio-engineered R stents accelerate re-endothelialization and reduce thrombogenicity vs BMS via progenitor cell capture.
Why the study?
The Genous Bio-engineered R stent aims to promote vascular healing by capturing circulatory endothelial progenitor cells to accelerate re-endothelialization, but its function compared to bare-metal stents in human and animal circulation needed assessment.
Does the Genous Bio-engineered R stent improve re-endothelialization and reduce thrombogenicity compared to bare-metal stents in ex vivo and animal models?
Does the Genous Bio-engineered R stent improve re-endothelialization and reduce thrombogenicity compared to bare-metal stents in ex vivo and animal models?
The Genous bio-engineered EPC-capture stent accelerates re-endothelialization and reduces thrombogenicity compared to bare-metal stents in ex vivo and animal models.
Supports EPC-capture stents for reduced thrombogenicity in ex vivo models; leaves open translation to clinical outcomes.
AIMS: The Genous™ Bio-engineered R™ stent (GS) aims to promote vascular healing by capture of circulatory endothelial progenitor cells (EPCs) to the surface of the stent struts, resulting in accelerated re-endothelialization. Here, we assessed the function of the GS in comparison to bare-metal stent (BMS), when exposed to the human and animal circulation. METHODS AND RESULTS: First, 15 patients undergoing coronary angiography received an extracorporeal femoral arteriovenous (AV) shunt containing BMS and GS. Macroscopical mural thrombi were observed in BMS, whereas GS remained visibly clean. Confocal and scanning electron microscopic (SEM) analysis of GS showed an increase in strut coverage. Quantitative polymerase chain reaction (qPCR) analysis of captured cells on the GS demonstrated increased expression of endothelial markers KDR/VEGFR2 and E-selectin, and a decrease in pro-thrombogenic markers tissue factor pathway inhibitor and plasminogen activator inhibitor-1 compared with BMS. Secondly, a similar primate AV shunt model was used to validate these findings and occlusion of BMS was observed, while GS remained patent, as demonstrated by live imaging of indium-labelled platelets. Thirdly, in an in vitro cell-capture assay, GS struts showed increased coverage by EPCs, whereas monocyte coverage remained similar to BMS. Finally, the assessment of re-endothelialization was studied in a rabbit denudation model. Twenty animals received BMS and GS in the aorta and iliac arteries for 7 days. Scanning electron microscopic analysis showed a trend towards increased strut coverage, confirmed by qPCR analysis revealing increased levels of endothelial markers (Tie2, CD34, PCD31, and P-selectin) in GS. CONCLUSION: In this proof-of-concept study, we have demonstrated that the bio-engineered EPC-capture stent, Genous™ R™ stent, is effective in EPC capture, resulting in accelerated re-endothelialization and reduced thrombogenicity.
No takes yet. Share an insight, caveat, or question.
Larsen et al. (2011) studied Patients undergoing coronary angiography (n=15). Genous Bio-engineered R stent (GS) vs. Bare-metal stent (BMS) was evaluated on Stent strut coverage, re-endothelialization, and thrombogenicity. The Genous Bio-engineered R stent demonstrated effective endothelial progenitor cell capture, resulting in accelerated re-endothelialization and reduced thrombogenicity compared with bare-metal stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: